Zai Lab Reports Q2 2026 Revenue of $106.3 Million
Zai Lab reported total revenues of $106.3 million in Q2 2026, achieving sequential growth driven by ZEJULA and VYVGART. The company highlighted multiple clinical pipeline advancements and confirmed momentum for potential regulatory filings next year.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day